U.S. Consumer Advocate Urges U.S. Inspection Of Shanghai Hualian Plants
This article was originally published in PharmAsia News
A U.S. consumer advocate says the U.S. FDA should inspect immediately all the plants of China's Shanghai Hualian drug maker in the wake of last year's scandal at one of its plants. Two officials of Shanghai Hualian, a division of Shanghai Pharmaceutical Group, were detained by Shanghai police during an investigation after nearly 200 cancer patients were harmed by Hualian leukemia drugs made at one of the division's plants that also produces mifepristone. The drug ingredient is the primary ingredient in the abortion drug RU-486. The division is the sole supplier of the controversial abortion drug, but a Shanghai regulator said the leukemia and RU-486 drugs were made at two different plants. Danco Laboratories has U.S. clearance for the drug as Mifeprex. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.